Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
IL1R2+ Treg depletion using IL1R2-targeting ADCC-prone constructs is a potential cancer therapy to selectively target tumor-infiltrating Tregs and circumvent autoimmune complications caused by systemic Treg depletion.
Authors
- Gillian Blancke (ORCID: https://orcid.org/0000-0002-1748-9653)
- Jan Brughmans (ORCID: https://orcid.org/0000-0003-0839-0990)
- Catelijne Stortelers (ORCID: https://orcid.org/0000-0002-7722-1042)
- Louis Boon (ORCID: https://orcid.org/0000-0002-0937-9171)
- Máté Kiss (ORCID: https://orcid.org/0000-0002-5649-0382)
- Romina Mora Barthelmess (ORCID: https://orcid.org/0000-0003-1384-4483)
- Geert Raes (ORCID: https://orcid.org/0000-0002-9065-1549)
- Sana M. Arnouk (ORCID: https://orcid.org/0000-0003-2045-6729)
- Cécile Vincke (ORCID: https://orcid.org/0000-0003-0681-7444)
- Timo W.M. De Groof (ORCID: https://orcid.org/0000-0001-6918-2955)
- Els Lebegge (ORCID: https://orcid.org/0000-0001-9671-4363)
- Lars Vereecke (ORCID: https://orcid.org/0000-0002-1593-862X)
- Yvon Elkrim (ORCID: https://orcid.org/0000-0003-1432-456X)
- Bruno Dombrecht (ORCID: https://orcid.org/0000-0003-3824-3975)
- Aleksandar Murgaski (ORCID: https://orcid.org/0000-0002-5606-2230)
- Ramses Forsyth (ORCID: https://orcid.org/0000-0001-8337-5382)
- Jo A. Van Ginderachter (ORCID: https://orcid.org/0000-0002-4442-7474)
- Helena Van Damme (ORCID: https://orcid.org/0000-0002-1042-2907)
- Ayla Debraekeleer (ORCID: https://orcid.org/0000-0002-3109-9862)
- Nick Devoogdt (ORCID: https://orcid.org/0000-0001-9220-4833)
- Guillaume E. Courtoy (ORCID: https://orcid.org/0000-0001-9311-2105)
- Daliya Kancheva (ORCID: https://orcid.org/0000-0001-6222-0461)
- Damya Laoui (ORCID: https://orcid.org/0000-0002-3373-1403)
- Wim Waelput (ORCID: https://orcid.org/0000-0002-4433-5852)
- Yves Heremans (ORCID: https://orcid.org/0000-0002-2608-974X)
- Emile Clappaert (ORCID: https://orcid.org/0000-0003-1748-8666)
- Jolien Van Craenenbroeck (ORCID: https://orcid.org/0009-0000-1795-3957)
- Naela Assaf (ORCID: https://orcid.org/0009-0009-3188-6346)
- Nadja van Boxel (ORCID: https://orcid.org/0009-0001-0058-6203)
Institutions
- Vrije Universiteit Brussel (BE)
- Discovery Centre (CA)
- Ghent University Hospital (BE)
- Ghent University (BE)
- VIB-UGent Center for Plant Systems Biology (BE)
- Pure Biologics (Poland) (PL)
- Cancer Research Institute Ghent (BE)
- Universitair Ziekenhuis Brussel (BE)
- VIB-UGent Center for Inflammation Research (BE)
- VIB-VUB Laboratory Myeloid Cell Immunology (BE)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1158/0008-5472.can-24-3095
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Fonds Wetenschappelijk Onderzoek
- Vrije Universiteit Brussel
- Kom op tegen Kanker
- Fondation contre le Cancer